

Mauna Lani Bay Hotel & Bungalows

The Mauna Lani Bay Hotel and Bungalows is not just a hotel, but a secluded oceanfront playground set on three miles of pristine coastline. The name Mauna Lani means mountain reaching heaven, a name given by the Hawaiian elders. Embrace the spirit of aloha and share the love for Hawai'i - the weather, beaches, tropical energy, unique island culture and most importantly, the people. The feeling of being in Hawai'i will overcome you as you enter Mauna Lani's breezy atrium: cascading waterfalls, lush foliage, the sound of tropical songbirds, and ponds filled with colorful koi fish and baby green sea turtles. The Mauna Lani invites you to experience paradise. Each guest room has a private lanai, one of the best places on island for whale watching.

The Mauna Lani Bay Hotel & Bungalows

68-1400 Mauna Lani Drive Phone 808-885-6622
Kohala Coast, Fax 808-881-7000
Island of Hawai'i 96743 www.maunalani.com

2016 GOLF WEEKS MAGAZINE - Best Courses to Play - Mauna Lani is ranked as one of the Best Courses to play in Hawaii. Mar. 2016

2015 TRIP ADVISOR - Certificate of Excellence 2015 and Hall of Fame Winner - Mauna Lani consistently earns outstanding feedback from TripAdvisor travelers. June 2015

2014 CONDÉ NAST TRAVELER - Reader's Choice Award for Best in the World - Mauna Lani Bay Hotel & Bungalows is ranked in the Top 25 Hawaii Resorts. Oct 2014

2014 TRAVEL + LEISURE - World's Best Awards - Mauna Lani Bay Hotel & Bungalows is ranked in the Top 25 Hawaii Resorts by Travel + Leisure magazine's Reader Poll. Aug 2014

SPECIAL ACCOMMODATION RATE FOR THE SYMPOSIUM VALID ONLY UNTIL : November 17, 2017

\$195 Garden View or Standard

\$240 Ocean View

\$260 Deluxe Ocean View

\$315 Ocean Front

These Rates are subject to availability and to the prevailing Hawaii State General Excise and Room Occupancy Taxes, currently at a combined rate of 13.4166% (subject to change) and a \$15 Resort Activity Package.

Hotel Reservation Deadline: November 17, 2017

If your reservation is not received prior to cut-off date, reservations will only be accepted subject to availability. Please specify that you plan to attend the 7th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure so you can receive our special symposium rate.

Reservations can be booked via hotel link at:

ccmmeetings.com

or call hotel's reservations department directly at:

1-800-367-2323

COURSE DESCRIPTION CME ACCREDITATION

The 7th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure will be held from **Nov 30 - Dec 2** at the delightful Mauna Lani Hotel on the beautiful Island of Hawaii. This year we have put together a program that is designed to provide in depth coverage of the important advances that have taken place in heart failure over the past year as well as provide an overview of the most effective therapeutic strategies for prevention and treatment. Topics that will be covered through a series of lectures, panel discussions and case presentations include:

- Lipid lowering strategies and the role of PCSK9 inhibitors
- Can treating diabetes prevent heart failure?
- Best approaches for managing hypertension
- Update on the use of biomarkers
- Evaluation and treatment of sleep apnea
- Overview of new heart failure drugs
- Pulmonary arterial hypertension
- Understanding HFpEF
- NOAC's and atrial closure devices for atrial fibrillation
- Role of palliative care and hospice
- Percutaneous approaches for treating valvular disease
- What's new with pacing, ICDs and CRT
- Emerging approaches for treating heart failure
- Managing acute heart failure

Attendees will have the opportunity to hear leaders in the field discuss the newest important advances as well as provide practical guidance for optimizing patient care. We hope that you will decide to join us.

SYMPOSIUM OBJECTIVES

At the end of the meeting the participant will be better able to:

1. Implement effective therapy for treating heart failure patients with pharmacologic agents and devices
2. Recognize the role of new FDA approved heart failure drugs
3. Describe new anticoagulants to treat atrial fibrillation and other cardiovascular diseases
4. Define patients who are candidates for the use of left atrial appendage closure devices
5. Determine how remote monitoring devices and biomarkers help in patient management
6. Evaluate and manage patients with pulmonary arterial hypertension
7. Define indications for percutaneous mitral repair and aortic valve replacement
8. Identify patients who are candidates for ICDs and CRT
9. Describe the value of a wearable cardioverter defibrillator
10. Explore novel "biomarkers" such as pulmonary pressure, serum potassium, apnea/hypopnea index, and how this will lead to new and effective targeted therapies
11. Describe new agents to treat hypercholesterolemia and diabetes

TARGET AUDIENCE

The target audience for this activity includes Cardiologists, Internists, Primary Care Physicians, Nurses, Nurse Practitioners, Physician Assistants, PharmDs and Allied Health Care Professionals.



This Live activity, **7th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure**, with a beginning date of November 30, 2017 has been reviewed and is acceptable for up to **14.75** Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to *AMA PRA Category 1 Credit™* toward the AMA Physician's Recognition Award.

AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AAFP Prescribed credit.

ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.

AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.

NEEDS ASSESSMENT

Nearly 6 million Americans (two percent of the U.S.) are living with heart failure. An estimated 670,000 new cases of heart failure (HF) are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the US. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010;16: 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).

Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the US on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010). Using data from the IMPROVE-HF registry it was found that only 7% of HF patients received all therapies for which they were potentially eligible and use of guideline recommended therapy by practices varied widely (Fonarow GC et al Circ Heart Failure 2008;1:98).

The importance of correcting deficiencies in knowledge and practice is evidenced from the results of recent studies demonstrating that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (OPTIMIZE- HF, JAMA 2007; 297: 61).

Officially endorsed by the **Heart Failure Society of America**. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.

CANCELLATIONS

Because of advance planning requirements, a full refund less a \$75.00 processing fee will be given if you cancel. Please cancel in writing and postmark by **November 2, 2017**. No refunds will be given after **November 2, 2017**.

FOR FURTHER INFORMATION

Complete Conference Management
3320 Third Avenue, Suite C
San Diego, CA 92103

PH 619-299-6673
FAX 619-299-6675
Email: info@ccmmeetings.com
Conference website: www.ccmmeetings.com

International Hawaii Symposium on DTMHF

3320 Third Avenue, Suite C
San Diego, CA 92103

The 7th Annual
International Hawaii Symposium on
Diagnostic and Therapeutic Modalities in Heart Failure

A Comprehensive and Practical Review of
Advances in Heart Failure and Biomarkers

November 30 - December 2, 2017

The Mauna Lani Bay
Hotel & Bungalows

ccmmeetings.com

If you receive more than one brochure
please pass the extra along to an associate.

PLEASE POST

The 7th Annual
International Hawaii Symposium on
Diagnostic and Therapeutic Modalities in
Heart Failure
A Comprehensive and Practical Review of
Advances in Heart Failure and Biomarkers

November 30 - December 2, 2017
The Mauna Lani Bay Hotel
Kohala Coast, Island of Hawaii

Program Directors:
Barry H. Greenberg, MD
Alan Maisel, MD

Officially Endorsed by:

Arizona, California, Hawaii ACC Chapters

UCSD Sulpizio Cardiovascular Center
ccmmeetings.com

"My time was well spent at this symposium!" P.S.

"What could be better? Being in Paradise while learning more about the latest update in heart failure treatment." A.S.

"You hit on the right topics for this program!" D.S.

FACULTY

PROGRAM DIRECTORS



Barry H. Greenberg, MD, FACC
Distinguished Professor of Medicine
Director, Advanced Heart Failure
Treatment Program
UC San Diego
San Diego, CA



Alan Maisel, MD, FACC
Professor of Cardiology, UCSD
Director, Coronary Care Unit and
Heart Failure Program
San Diego Veterans Affairs
Medical Center
San Diego, CA

FACULTY



Eric Adler, MD
Associate Clinical Professor
Medical Director, Cardiac Transplant
UC San Diego
San Diego, CA



James C. Fang, MD
Professor of Medicine
John and June B Hartman Presidential
Endowed Chair
Chief, Division of Cardiovascular Medicine
Executive Director, Cardiovascular Service Line
University of Utah
Salt Lake City, UT



Nancy Albert, PhD
Associate Chief Nursing Officer
Nursing Institute
Research and Innovation and
Clinical Nurse Specialist
Heart and Vascular Institute
Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, OH



Gregg Fonarow, MD, FACC, FAHA
Professor of Medicine
Director, Ahmanson - UCLA
Cardiomyopathy Center
Co-Chief, UCLA Division of Cardiology
University of California, Los Angeles
Los Angeles, CA



Daniel Blanchard, MD, FACC
Professor of Clinical Medicine
Division of Cardiovascular Medicine
UC San Diego
San Diego, CA



Paul Hansen, PharmD, BCACP
Clinical Pharmacist
PGY2 Residency Program Director,
Transitions of Care
Assistant Clinical Professor
Skaggs School of Pharmacy and
Pharmaceutical Sciences at UC San Diego
San Diego, CA



John Chin, MD, FACC
Professor of Medicine
California Northstate University
College of Medicine
Associate Clinical Professor of Medicine
University of California, Davis
Medical Director, Advanced CHF:
Cardiac Transplant, Sutter Hospital
Sacramento, CA



David Krummen, MD, FACC
Professor of Medicine
Director of Cardiac Electrophysiology
VA San Diego Healthcare System
Electrophysiologist, UCSD and
VA San Diego
San Diego, CA



Lori Daniels, MD, MAS, FACC
Professor of Medicine
Director, Coronary Care Unit
Division of Cardiology
UC San Diego
San Diego, CA



David Singh, MD
Electrophysiologist
The Queens Medical Center
Associate Professor of Medicine
John A Burns School of Medicine
University of Hawaii
Honolulu, HI



Uri Elkayam, MD, FACC
Professor of Medicine
Director of Cardiology
University of Southern California
Los Angeles, CA



Pam R. Taub, MD, FACC
Associate Professor of Medicine
Director of Hannah and
Gene Step Cardiac Wellness &
Rehabilitation Center
Division of Cardiovascular Medicine
UC San Diego
San Diego, CA

FACULTY DISCLOSURE It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker's outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

PROGRAM

Thursday, November 30, 2017

7:00am	Registration Opens
7:15-8:15	Continental Breakfast
SESSION I	Heart Failure Prevention - Barry Greenberg, MD (Moderator)
8:15-8:35	Treating Hypertension in 2017 - After SPRINT What Makes the Most Sense? Daniel Blanchard, MD
8:35-8:55	Can Treating Diabetes with SGLT2 Inhibitors Prevent Heart Failure? Gregg Fonarow, MD
8:55-9:15	Results of Recent Trials with PCSK9 Inhibitors Lori Daniels, MD
9:15-9:35	Cardiac Rehabilitation for Heart Failure Patients - Why, Who and How? Pam Taub, MD
9:35-10:10	Case Presentation and Questions Pam Taub, MD (Presenter), Drs. Blanchard, Fonarow, Daniels, Greenberg and Paul Hansen, PharmD (Panelists)
10:10-10:35	Break/Visit Exhibits
SESSION II	Biomarkers/HFpEF/NOACs - Alan Maisel, MD (Moderator)
10:35-10:55	Biomarkers I: Defining the Value of Measuring Alan Maisel, MD
10:55-11:20	HFpEF - Unraveling the Causes and Finding New Treatments Barry Greenberg, MD
11:20-11:40	The Use of NOACs in Cardiovascular Disease - New Information, New Approaches Lori Daniels, MD
11:40-12:10	Biomarkers II: Novel and Emerging Biomarkers Alan Maisel, MD
12:10-1:15	Lunch - Product Theatre (Non-CME) Repatha® (evolocumab): A Focused Clinical Review Pam Taub, MD Support Provided by Amgen
SESSION III	New Modalities of Heart Failure Therapy
PM	John Chin, MD (Moderator)
4:00-4:20	Why and How to Use Combined Nephilysin and Angiotensin Inhibition (ARNI) Therapy Gregg Fonarow, MD
4:20-4:40	Value of SHIFTing to a Lower Heart Rate with Ivabradine Uri Elkayam, MD
4:40-5:00	Treating Hyperkalemia-Why and How James Fang, MD
5:00-5:25	New and Emerging Heart Failure Drugs Barry Greenberg, MD
5:25-5:45	Natroceuticals and other OTC Drugs Paul Hansen, Pharm D
5:45-6:10	Audience Questions - John Chin, MD (Moderator) Drs. Fonarow, Greenberg, Elkayam, Fang and Paul Hansen, PharmD (Panelists)
6:10	Adjourn

Friday, December 1, 2017

7:00am	Registration Opens
7:15-8:15	Breakfast - Product Theatre (Non-CME) Thrombosis: AFib an Exploration in Risk Reduction Uri Elkayam, MD Support Provided by Janssen
SESSION IV	Pulmonary HTN, Sleep Apnea and CAD
AM	Eric Adler, MD (Moderator)
8:15-8:40	Pulmonary Artery Hypertension I: Diagnosis and Classification James Fang, MD
8:40-9:00	Diagnosing and Treating Sleep Apnea Alan Maisel, MD
9:00-9:20	Wearables and Implantables for Our Patients Pam Taub, MD
9:20-9:40	Pulmonary Artery Hypertension II: New and Emerging Therapies James Fang, MD
9:40-10:10	Case Discussion - Dr. Fang (Presenter) Drs. Taub, Maisel, Chin and Greenberg (Discussants)
10:10-10:30	Break/Visit Exhibits
SESSION V	Rhythm and Exercise - Uri Elkayam, MD (Moderator)
10:30-10:55	Optimizing the Management of Atrial Fibrillation Including Atrial Closure Devices David Krummen, MD
10:55-11:20	Role of the Wearable Cardioverter Defibrillator (WCD) Barry Greenberg, MD
11:20-11:45	Advances in CRT: What is the Impact for the Patient with Heart Failure? David Krummen, MD
11:45-12:10	New Pacing Approaches and Strategies David Singh, MD
12:10-12:25	Panel Discussion and Audience Questions Dr. Elkayam (Moderator), Drs. Krummen, Greenberg and Singh (Panelists)
12:25-1:30	Lunch - Product Theatre (Non-CME) Optimizing Treatment to Improve Outcomes: Implementing the New Guideline for Managing Heart Failure With Reduced Ejection Fraction - Barry Greenberg, MD Support Provided by Novartis Pharmaceuticals Corporation
SESSION VI	Practical Approaches to Acute Heart Failure and Transitions of Care - Gregg Fonarow, MD (Moderator)
PM	
4:00-4:35	Management Strategies for Acute Heart Failure Barry Greenberg, MD
4:35-5:00	Temporary Percutaneous Circulatory Support Eric Adler, MD
5:00-5:35	Optimizing Transitions of Care Nancy Albert, PhD
5:35-6:00	Remote Monitoring of Pulmonary Artery Pressures Gregg Fonarow, MD

Saturday, December 2, 2017

7:00am	Registration Opens
7:15-8:15	Breakfast - Product Theatre (Non-CME) High Sensitive Troponins - There are NO False Positives Alan Maisel, MD and Robin J. Trupp, PhD, RN Support Provided by Roche Diagnostics
SESSION VII	Advances in Managing End-Stage Heart Failure
	Barry Greenberg, MD (Moderator)
8:15-8:40	Defining End-Stage Heart Failure Eric Adler, MD
8:40-9:05	Role of Palliative Care and Hospice Nancy Albert, PhD
9:05-9:30	Transplant and VADs Eric Adler, MD
9:30-9:50	Managing Hyponatremia John Chin, MD
9:50-10:15	Questions/Case Presentation - Dr. Adler (Presenter) Drs. Greenberg, Elkayam, Fang and Albert (Discussants)
10:15-10:40	Break/Visit Exhibits
SESSION VIII	Topics in Heart Failure - Alan Maisel, MD (Moderator)
10:40-11:05	Treatment with Hydralazine and Nitrates Uri Elkayam, MD
11:05-11:30	Let's Not Forget about Cardiac Auscultation: New Advances in the Stethoscope Alan Maisel, MD
11:30-12:00	3rd Annual Echo Imaging Quiz - Fascinomas Included at No Extra Charge Daniel Blanchard, MD
12:00	Meeting adjourned until December 2018!



REGISTRATION FORM

For online registration visit: www.ccmmeetings.com

Last Name	Title	
First Name	MI	
Office Address		
City	State	Zip
Daytime Phone	Fax	
Email Address		
Professional Specialty		
Special Needs for Disabled		

REGISTRATION FEES: Please enroll early, registration is limited.

PHYSICIAN / OTHER

\$550	Super Early Bird - on or before Oct. 2, 2017
\$650	Pre-Registration - on or before Nov. 1, 2017
\$750	After Nov. 1, 2017 and on-site
\$250	Single Day <input type="checkbox"/> Nov. 30 <input type="checkbox"/> Dec. 1 <input type="checkbox"/> Dec. 2 (one use only, please make selection)

FELLOWS / RESIDENTS / NURSES / ALLIED MED. PERS.

\$375	Super Early Bird - on or before Oct. 2, 2017
\$475	Pre-Registration - on or before Nov. 1, 2017
\$575	After Nov. 1, 2017 & on-site
\$150	Single Day <input type="checkbox"/> Nov. 30 <input type="checkbox"/> Dec. 1 <input type="checkbox"/> Dec. 2 (one use only, please make selection)

OPTIONAL SESSIONS (indicate choice - breakfast/lunch included)

- I will attend 12:10 p.m. lunch session on **Nov 30**
- I will attend 7:15 a.m. breakfast session on **Dec 1**
- I will attend 12:25 p.m. lunch session on **Dec 1**
- I will attend 7:15 a.m. breakfast session on **Dec 2**

Checks Payable to: Diagnostic and Therapeutic Modalities in Heart Failure	Mail to: Complete Conference Management 3320 Third Avenue, Suite C San Diego, CA 92103 Fax to: 619-299-6675
---	--

CREDIT CARD INFORMATION:

(Visa, Mastercard, American Express & Discover ONLY)

Card Number	\$	
Exp. Date	Security Code	Amount
Name on Card		
Billing Address		
Signature		

Symposium will not refund travel costs in the event of a course cancellation.